Amarin to Report Second Quarter 2020 Results and Host Conference Call on August 4, 2020GlobeNewsWire • 07/21/20
Amarin Analysts Say Vascepa Patent Settlement Not A Stock Mover, With 'Little Readthrough For Pending Patent Appeal'Benzinga • 06/17/20
VASCEPA® (icosapent ethyl) Shows Significant Cardiovascular Risk Reduction in People with Diabetes in Prespecified and Post Hoc Subgroup Analyses of Landmark REDUCE-IT® StudyGlobeNewsWire • 06/15/20
Generic Threat To Amarin's Vascepa Overrides Positive Sentiment On Coronavirus AnnouncementBenzinga • 05/22/20
Amarin Supports Trial to Investigate the Effects of VASCEPA® (icosapent ethyl) in the Treatment of COVID-19GlobeNewsWire • 05/21/20